The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 18 and 19 October 2017 it purchased 256,520 and 193,100 ordinary shares of 1p each, respectively, in the capital of the Company ("Ordinary Shares") at an average price of 3.075p per Ordinary Share (the “Purchase”) and on 20 October it purchased 119,636 ordinary shares of 1p each at a price of 3.15p per Ordinary Share. Following the Purchase, Vulpes has a total direct and indirect interest in 55,012,971 equivalent to 18.64% of Proteome Sciences' total issued share capital.
The Company is pleased to announce the receipt of Good Clinical Laboratory Practice (GCLP) accreditation which will now enable it to compete effectively for clinical stage contracts commanding routinely larger budgets; the benefits of this should start being reflected early in 2018.
Commenting on this update Jeremy Haigh, Chief Executive Officer of Proteome Sciences, said “We are working hard to establish Proteome Sciences as a successful services business and are beginning to see the benefits of the comprehensive restructuring and refocusing which was initiated earlier in the year. While we would have liked greater progress to date, revenues continue to grow well and we are witnessing a material increase in enquiry and engagement levels during the second half, particularly from the US. We remain confident that this can be reliably converted into service-based revenues in the near to medium term and are pleased that increasing demand for our TMT® reagents continues to underpin our overall revenue growth and prospects.”
Proteome Sciences (AIM:PRM), announces that it has today issued and allotted 533,333 ordinary shares of 1p each in the capital of the Company (“Ordinary Shares”) as payment for professional services.
Proteome Sciences (AIM:PRM), is pleased to announce the appointment of Dr Ursula Ney as a Non-executive Director of the Company, with immediate effect, replacing Professor William Dawson who is standing down after providing 20 years of valuable service to the Company.
Commenting on these results, Jeremy Haigh, Chief Executive Officer of Proteome Sciences, said:
“We are pleased to report that performance during the first six months of 2017 has been broadly in line with expectations, and revenues significantly ahead of the equivalent period in 2016 driven by strong growth in TMT® sales. This was achieved despite predictable disruption resulting from the consolidation of our laboratory capabilities in Frankfurt and the relocation of our head office to London; these activities increased our administrative expenses for the period compared with 2016 but are expected to generate cost savings from the second half of 2017 onwards....."
Proteome Sciences will announce its interim results for the six months ended 30 June 2017 on 25 July 2017.
We are pleased to announce that Randox Laboratories Ltd, (“Randox”) presented the first results from a prospective trial using its Rapid Stroke Array at the EuroMedLab 2017 meeting in Athens earlier this month. This is a novel diagnostic test designed to improve the clinical management of stroke and is based on multiple biomarkers some of which have been licensed from Proteome Sciences and developed in association with the Biomedical Proteomics Research Group at the University of Geneva.
Proteome Sciences plc (AIM:PRM) is pleased to announce that its corporate headquarters have moved from Cobham to new premises in central London.
The Company has received notification from Vulpes Life Sciences Fund ("Vulpes") that on 10 May 2017 it purchased 97,314 ordinary shares of 1p each in the capital of the Company ("Ordinary Shares") at a price of 5p per Ordinary Share (the “Purchase”). Following the Purchase Vulpes has a total direct and indirect interest in 54,443,715 equivalent to 18.48% of Proteome Sciences' total issued share capital.